The AP2 transcription factor family is a set of developmentally regulated, retinoic acid inducible genes composed of four related factors, AP2␣, AP2␤, AP2␥, and AP2␦. AP2 factors orchestrate a variety of cell processes including apoptosis, cell growth, and tissue differentiation during embryogenesis. In studies of primary malignancies, AP2␣ has been shown to function as a tumor suppressor in breast cancer, colon cancer, and malignant melanoma. In cell culture models, overexpression of AP2␣ inhibits cell division and stable colony formation, whereas, a dominant-negative AP2␣ mutant increases invasiveness and tumorigenicity. Here we show that AP2␣ targets the p53 tumor suppressor protein.
The AP2 transcription factor family is a set of developmentally regulated, retinoic acid inducible genes composed of four related factors-AP2␣, AP2␤, AP2␥, and AP2␦ (1) (2) (3) (4) . AP2 factors orchestrate a variety of cell processes including apoptosis, cell growth, and tissue differentiation during embryogenesis (5, 6) . Studies in AP2 knock-out mice have indicated an important role for AP2 factors in the development of neural crest, epidermal, and urogenital tissues (5-9). AP2 factors have been shown to regulate the expression of genes in various tissues and tumors. In melanoma cells, AP2 has been shown to regulate the MUC18 and c-KIT promoters (10) . AP2␣ and AP2␥ appear to be coordinately involved in regulating the basal and cAMP-induced expression of human chorionic gonadotropin in the placenta (11) . In breast cancer, the AP2 factors have been implicated in the regulation of the ErbB2 (3, 12) and ER␣ genes (13, 14) .
Several lines of investigation have led to the conclusion that AP2␣ is a tumor suppressor gene. Studies of primary breast tumors using immunohistochemistry demonstrated a progressive loss of AP2␣ expression with tumor progression from normal mammary epithelium, to DCIS, and to invasive cancer (15) . Similar findings have been reported for colon carcinomas evaluated by immunohistochemistry, which demonstrated a decrease in AP2␣ expression in advanced Duke's stage carcinomas (16) . Interestingly, there was an increase in AP2␣ mRNA in advanced stage colon tumors as determined by in situ hybridization indicating that the loss of AP2␣ was at the level of protein synthesis or stability. Loss of AP2␣ expression has also been reported to occur with malignant transformation and tumor progression in cutaneous malignant melanoma (17) . Decreased AP2␣ expression was found to be independently associated with elevated risk of subsequent metastatic behavior of stage I cutaneous malignant melanoma. In cell culture models, AP2␣ has been reported to activate p21 WAF1/CIP1 expression resulting in an inhibition of both cell division and stable colony formation (18) . Furthermore, a dominant-negative AP2␣ mutant has been shown to increase invasiveness and tumorigenicity (10, 19, 20) . These finding have been corroborated in studies of primary breast cancers and colorectal carcinomas, which demonstrated a significant correlation between AP2␣ and p21 WAF1/CIP1 expression (15, 21) . Similar studies have demonstrated an association between AP2␣ and p21 WAF1/CIP1 expression in stage I cutaneous malignant melanoma (17) .
We have identified a direct protein-protein interaction between AP2␣ and the p53 tumor suppressor protein. The interaction between AP2␣ and p53 was demonstrated in vitro by yeast two-hybrid and GST 1 pull-down and was confirmed in vivo by co-immunoprecipitation, co-localization and chromatin immunoprecipitation (ChIP). Furthermore, ChIP analysis demonstrated that AP2␣ is targeted to the p53 binding sites in p53-regulated promoters. The interaction between AP2␣ and p53 resulted in an augmentation of p53-mediated transcriptional activation, which was evident by reporter assays and by induction of endogenous p21 WAF1/CIP1 expression. Consistent with this finding was that AP2␣ induced G 1 and G 2 cell cycle arrest only in the presence of p53. We conclude that the tumor suppressor activity of AP2␣ is mediated through a direct interaction with p53. The interaction between AP2␣ and p53 provides a mechanism to explain patterns of gene expression in tumors where AP2␣ has been shown to act as a tumor suppressor.
MATERIALS AND METHODS
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was amplified from the SP(RSV)AP2 plasmid (Gift of Trevor Williams, University of Colorado) using the primers 5Ј-CGATCCATGCATAT-GCTTTGGAAATTGACG-3Ј and 5Ј-GGGAGGGTCGACTCACTTTCT-GTGCTTCTC-3Ј. After NdeI/SalI digestion, the PCR product was ligated into pGBKT7 (Clontech, Palo Alto, CA). To generate DNA-BD/ AP2␥ and AD/AP2␥, the full-length AP2␥ coding region was amplified using the primers 5Ј-ACGCCGGACCATATGTTGTGGAAAATAACC-3Ј and 5Ј-TCGTTGGATCCTTATTTCCTGTGTTTCTCC-3Ј (for DNA-BD/ AP2␥) or 5Ј-TCGTTCTCGAGTTATTTCCTGTGTTTCTCC-3Ј (for AD/ AP2␥). The PCR products were digested and ligated into the NdeI/ BamHI site of pGBKT7 for DNA-BD/AP2␥ and into the NdeI/XhoI site of pGADT7 (Clontech Inc.) for AD/AP2␥. DNA-BD/p53 and AD/T were obtained from Clontech Inc.
GST Pull-down Assay-Radiolabeled p53 was synthesized using T7 polymerase and the TNT-coupled transcription/translation kit (Promega, Madison, WI). The AP2␣-GST fusion construct, AP2␣/pGEX-4T-3, was made by PCR using primers 5Ј-CGATCCGTCGACATGCTTTGGAAAT-TGACG-3Ј and 5Ј-GGGAGGGTCGACTCACTTTCTGTGCTTCTC-3Ј. After SalI digestion, the PCR fragment was ligated into pGEX-4T-3 (Amersham Biosciences). AP2␥/pGEX-4T-1 has been described previously (22) . The GST-p53 protein was obtained from Santa Cruz Biotecnology (Santa Cruz, CA). Fusion proteins were expressed in DH5␣ and purified by glutathione-Sepharose beads (Amersham Biosciences). 50 g of GST or GST fusion proteins were incubated with 20 l of a 50% slurry of glutathione-Sepharose 4B beads for 5 min at room temperature in 500 l of phosphate-buffered saline. The beads were washed four times with 500 l of 1ϫ phosphate-buffered saline and incubated with labeled p53 protein for 15 min at room temperature. The beads were washed, protein was eluted at room temperature for 5 min with glutathione elution buffer (10 mM reduced glutathione, 50 mM Tris, pH 8.0) and resolved on 8% SDS-PAGE.
Gel-shift Assay-Preparation of MCF7 nuclear extract and gel-shift analysis were performed as previously described (22) . AP2␣-specific antibody (C-18) and p53-specific antibodies (DO-1, FL-393, and Pab1801) (Santa Cruz Biotechnology) were used for supershift and/or immunoprecipitation. After immunoprecipitation, complexes were disrupted with 0.8 M KCl, and supernatant was assayed for AP2␣.
Indirect Immunofluorescence-MCF7 or HCT116 p53Ϫ/Ϫ and p53ϩ/ϩ cells (gift from Dr. Bert Vogelstein, Johns Hopkins University) (23) were plated on glass coverslips coated with Matrigel (BD Biosciences) at a density of 2 ϫ 10 4 cells/well in DMEM ϩ 10% FCS. After 3 h, HCT116 cells were infected with either AdWT or AdAP2␣ (24) at a MOI of 10 for 1 h in Optimem-1 (Invitrogen). Virus was removed and replaced with 1 ml of DMEM ϩ 10% FCS. After 24 h, cells were subjected to 6 Gy ␥-radiation in a 137 Cs irradiator and incubated an additional 2 h prior to performing indirect immunofluorescence. Indirect immunofluorescence was performed on both MCF7 and HCT116 cells using primary antibodies for AP2␣ (C-18) and p53 (DO-1) diluted to 0.4 g/ml and 2.4 g/ml, respectively. Secondary antibodies Alexa 488 goat anti-mouse IgG and Alexa 568 goat anti-rabbit IgG conjugates (Molecular Probes, Eugene, OR) were diluted 1:500 and incubated with the fixed cells for 45 min at room temperature.
Transient Transcription Assay-CV-1 cells were plated at 1.5 ϫ 10 5 /35-mm plate in DMEM ϩ 10% FCS. Cells were transfected using FuGENE 6 reagent (Roche Molecular Biochemicals) with 200 ng of p␤Gal-Control (Clontech), 200 ng of the p53 reporter PG13PyLUC (gift from Dr. Bert Vogelstein, Johns Hopkins University) (25) , 200 ng of AP2␣ expression vector AP2␣/pcDNA3.1 (22) , and either 0, 50, 100, or 200 ng of Rc/CMVhp53 or Rc/CMVhp53His175 (gifts from Dr. Bert Vogelstein, Johns Hopkins University) (25) . Total amount of DNA transfected was equalized to 1 g using salmon sperm DNA. Cell extracts were harvested at 24 h and assayed as previously described (22) .
Chromatin Immunoprecipitation-ChIP analysis of p21 promoter was performed as described (26) . HCT 116 p53ϩ/ϩ or p53Ϫ/Ϫ cells were infected with Ad-AP2␣ and after 18 h were treated with 8 Gy ␥-irradiation. Cells were harvested for ChIP 6 h after irradiation. Immunoprecipitation was performed with the anti-AP2␣ C-18 antibody, and primers for PCR amplification were 5Ј-CCTGCTTCCCAGGAACATGCTT and 5Ј-CTGCTGGCAGATCACATACCCTGT, which amplifies the region of the p21 promoter containing the p53 binding sites at Ϫ2250.
Northern Blot Analysis-HCT116 p53Ϫ/Ϫ and p53 ϩ/ϩ cells were plated in DMEM ϩ 10% FCS at 1 ϫ 10 6 cells/35-mm dish and incubated overnight. Cells were infected with either AdWT or AdAP2␣ at an MOI of 10 for 1 h. Virus was removed, replaced with DMEM ϩ 10% FCS, and incubated for 24 h. One set of cells was treated with 6 Gy ␥-radiation, and both sets of cells were incubated an additional 24 h prior to RNA isolation. Primers for amplifying the 473 bp P21 WAF1/CIP1 PCR fragment were 5Ј-GCACTCAGAGGAGGCGCCATGTC-3Ј and 5Ј-GGTAGAAATC-TGTCATGCTGGTCTGCCG-3Ј. Primers used to amplify the 191-bp GAPDH PCR fragment were 5Ј-CACATCGCTCAGACACCATG-3Ј and 5Ј-GCCATGGAATTTGCCATGGG-3Ј. Phosphorimaging was performed on a Molecular Dynamics (Sunnyvale, CA) phosphorimager, and quantitative values were obtained using ImageQuant software (Molecular Dynamics).
Cell Cycle Analysis-HCT116 p53ϩ/ϩ and p53Ϫ/Ϫ cells were infected with AdWT or AdAP2␣ and treated with ␥-radiation. The AdWT and AdAP2␣ adenoviruses co-express green fluorescent protein (GFP) and ten thousand GFP-positive cells were analyzed from each sample on a FACStar flow cytometer for propidium iodide (PI) fluorescence. Cells were analyzed for cell cycle by PI staining and fluorescenceactivated cell sorting as previously described (27) . Using untreated HCT116 p53Ϫ/Ϫ and HCT116 p53ϩ/ϩ cells as a fingerprint for cell cycle, the percentage of cells in G 1 and G 2 was determined.
RESULTS
In order to determine mechanisms of AP2 action, we used a yeast two-hybrid assay to identify factors that interact with AP2␣. The full-length AP2␣ protein was cloned as a fusion with the Gal4 DNA binding domain (DNA-BD/AP2␣) and was cotransfected with a human mammary cDNA library cloned as a fusion with the Gal4 activation domain. Approximately 2 ϫ 10 domain fusion construct (AD/p53) were able to grow on quadruple drop out media. Similarly, yeast were able to grow on selected media when co-transformed with plasmids in which p53 was expressed as a fusion with the Gal4 DNA binding domain (DNA-BD/p53), and AP2␥ was expressed as a fusion with the Gal4 activation domain (AD/AP2␥). The protein-protein interaction between p53 and the AP2 factors was confirmed using GST pull-down (see Fig. 1B ). Both AP2␣ and AP2␥ were cloned as GST fusion proteins and incubated with radiolabeled p53. Beads alone or GST protein were included as negative controls, neither of which demonstrated an interaction with p53. Radiolabeled p53 was shown to specifically interact with both AP2␣ and AP2␥, thus confirming a direct protein-protein interaction.
MCF7 breast carcinoma cells endogenously express both wild-type p53 and AP2 factors. This cell line was used to demonstrate an interaction between p53 and AP2 factors in vivo. As seen in Fig. 2A, AP2␣ activity was detected by gel-shift assay following immunoprecipitation from MCF7 nuclear extract by AP2␣-specific antibody. Similarly, AP2␣ was detected in MCF7 nuclear extract precipitated using antibodies specific for p53. Immunoprecipitation performed with an irrelevant antibody (anti-HA) failed to immunoprecipitate AP2 activity. The interaction between p53 and the AP2 factors was examined in intact cells using indirect immunofluorescence (Fig. 2B ). MCF7 cells examined by immunofluorescence demonstrate colocalization for p53 and AP2␣. The specificity of the assay was confirmed using HCT116 p53ϩ/ϩ colon carcinoma cells (23) treated with ␥-radiation and infected with an adenoviral vector expressing AP2␣ (AdAP2␣). Indirect immunofluorescence demonstrated nuclear co-localization of p53 and AP2␣. By contrast, infection with wild-type adenovirus (AdWT) demonstrated staining for p53 only and the HCT116 p53Ϫ/Ϫ cell line infected with AdAP2␣ demonstrated staining for AP2␣ only. Similar results were obtained in COS-1 cells transfected with an expression vector for p53 followed by infection with AdAP2␣ or AdWT (data not shown). These results confirm the yeast twohybrid and GST pull-down results and indicate that p53 and AP2␣ interact within the nucleus of intact cells under conditions in which both proteins are endogenously expressed.
The functional consequences of the p53-AP2␣ interaction was investigated by examining the effect of AP2␣ expression on p53-mediated transactivation. As shown in Fig. 3A , a p53-responsive reporter was assayed in CV-1 cells co-transfected with expression vectors for p53 and AP2␣. As expected, increasing the amount of p53 expression vector transfected resulted in a reproducible increase in expression from the reporter. Notably, co-expression of AP2␣ augmented p53-mediated transactivation from the reporter. Transfection of AP2␣ alone had a negligible affect on luciferase expression indicating that the effect of AP2␣ was dependent upon p53. Similar results were obtained in COS-1 cells (data not shown). Further confirmation of the dependence on p53 was obtained by using a His-175 mutant of p53, which lacks DNA binding (25) . The His-175 p53 mutant failed to induce expression from the reporter and cotransfection of AP2␣ had no effect on luciferase expression. These results indicate that AP2␣ is able to augment p53-mediated transactivation in a transient assay. Further evidence for AP2␣ augmentation of p53 transcriptional activation was sought by examining expression of the cyclin kinase inhibitor p21 WAF1/CIP1 , which is regulated by p53-mediated transactivation (28, 29) . Chromatin immunoprecipitation was used to examine the interaction between p53 and AP2␣ on the p21 WAF1/CIP1 promoter in HCT116 colon carcinoma cells that have an intact p53 gene (p53ϩ/ϩ) or have the p53 alleles disrupted (p53Ϫ/Ϫ) (23). ChIP was performed by immunoprecipitating with anti-AP2␣ antibody and assaying for the region of the p21 promoter at Ϫ2250 targeted by p53. This p53 binding site is far removed from the AP2 sites mapped from Ϫ95 to Ϫ103 (18). After cross-linking, anti-AP2␣ specifically precipitated the region of the p21 promoter targeted by p53 only in the p53ϩ/ϩ cells (see Fig. 3B ). This result indicates that AP2␣ interacts with this region of the p21 WAF1/CIP1 promoter through an association with p53.
Based on these observations, we hypothesized that AP2␣ would augment expression of p21 WAF1/CIP1 in the presence of p53. As seen in Fig. 4 , AP2␣ expression had no significant effect on p21 expression in HCT116 p53Ϫ/Ϫ cells. In HCT116 p53ϩ/ϩ cells, radiation increased the relative level of p21 mRNA from 4.00 Ϯ 0.13 to 5.95 Ϯ 0.36 (p Ͻ 0.01) (Fig. 4B) . In the presence of AP2␣, the effect of radiation on the relative levels of p21 was augmented from 3.27 Ϯ 0.66 to 9.07 Ϯ 1.19 (p ϭ 0.01). As seen in Fig. 4C , AP2␣ expression failed to have a statistically significant effect on induction of p21 mRNA in 1-4) , MCF7 extract precipitated with AP2-antibody (lanes 5 and 6), p53 antibodies (lanes 7-10), or hemagglutinin tag antibody (lanes 11 and 12) demonstrates that AP2 is immunoprecipitated with antibody to AP2 or p53. Gel shift is used as an assay for AP2 protein with the AP2 complex indicated by arrow and supershift with bracket. B, co-localization of AP2 and p53. Indirect immunofluorescence was used to examine localization of p53 (green) and AP2␣ (red) in MCF7, HCT116 p53ϩ/ϩ and HCT116 p53Ϫ/Ϫ cells. HCT116 p53ϩ/ϩ and HCT116 p53Ϫ/Ϫ cells were infected with either a wild type or AP2␣-expressing adenovirus followed by 6 Gy ␥-radiation. Confocal microscopy (merged) demonstrates nuclear colocalization (yellow) of p53 and AP2␣ in MCF7 and HCT116 p53ϩ/ϩ cells infected with AdAP2␣. the absence of p53. By contrast, in the presence of p53, AP2␣ augmented the induction of p21 expression with radiation from 1.49 Ϯ 0.11 to 2.84 Ϯ 0.21 (p Ͻ 0.005). These data are consistent with the luciferase reporter and ChIP results and demonstrate that AP2␣ is able to augment p53-mediated transactivation of the p21 WAF1/CIP1 promoter. The G 1 -S arrest that occurs after radiation is caused, at least in part, by p53-mediated transactivation of p21 WAF1/CIP1 (30 -32) . In addition, both p53 and p21 have been shown to be essential for maintaining the G 2 arrest after radiation (23). In order to demonstrate the physiologic relevance of increased p21 expression induced by AP2␣, we compared cell cycle regulation in HCT116 p53ϩ/ϩ and p53Ϫ/Ϫ cells following radiation either with or without AP2␣ expression. These results are shown in Fig. 5 . In HCT116 p53Ϫ/Ϫ cells, AP2␣ expression had no significant effect on cell cycle in cells unirradiated or irradiated with 6 Gy ␥-radiation. In HCT116 p53ϩ/ϩ cells in the absence of radiation, AP2␣ expression had no appreciable effect on G1 and had a slight effect on G2. However, AP2␣ expression in ␥-radiated cells induced a striking alteration in cell cycle with a statistically significant increase in the percent of cells in G 1 and G 2 -M. The increase of the percentage of cells in G 1 and G 2 -M represents an arrest of cells at these two cell cycle checkpoints. This physiologic response is consistent with the effect of AP␣ on expression of the endogenous p21 gene in HCT116 p53ϩ/ϩ cells. AP2␣ expression in ␥-radiated HCT116 p53ϩ/ϩ cells also induced a reduction in the percentage of apoptotic cells, and this effect was also dependent upon the presence of p53. The induction of p21 expression with associated changes in cell cycle is compelling evidence that the tumor suppressor activity of AP2␣ is mediated through an augmentation of p53 activity.
DISCUSSION
Mutations of the p53 gene are the most common alterations found in cancer with 40 -45% of all tumor types harboring p53 mutations (33) . The function of p53 as a tumor suppressor gene is directly related to its activity as a sequence-specific transcription factor (34, 35) . Mutations of p53 that are commonly found in cancers have diminished or absent sequence-specific transcriptional activity (36) , and these mutant p53 proteins lack the ability to induce cell cycle arrest or apoptosis. A number of genes have been identified as targets of p53 transactivation including p21 WAF1/CIP1 (28) , MDM2 (37), GADD45 (38), cyclin G (39) , and caveolin (40) . The expression of p53 target genes has been shown to be cell type-specific. The p21
WAF1/CIP1
gene is transactivated by p53 in most cell types (40) and has been shown to be critical for G 1 and G 2 cell cycle arrest following radiation (30 -32) .
We have demonstrated a direct protein-protein interaction between p53 and AP2␣, which results in an augmentation of p53-mediated transcriptional activation. An earlier study reported that expression of p21 WAF1/CIP1 was induced by AP2␣ and suggested that AP2␣ directly targeted the p21 promoter (18) . Our findings extend this observation and demonstrate that the mechanism of p21 transactivation by AP2␣ is dependent upon wild-type p53. Our results with ChIP analysis provide additional mechanistic evidence that p53 targets AP2␣ to the p53 binding sites in the p21 promoter. Clinical studies have demonstrated an association between AP2␣ and p21 expression in colon carcinoma (21) , breast cancer (15) , and stage I cutaneous malignant melanoma (17) . Interestingly, the association between AP2␣ and p21 expression is lost in late phases of melanoma progression (41) and ϳ10% of early stage melanomas will express AP2␣ but fail to express p21 (17) . Since our model predicts that the association between p21 and AP2␣ expression is dependent upon p53, the lack of correlation between p21 and AP2␣ in some tumors suggests the presence of certain p53 mutations that lose the ability to interact with AP2␣.
Our results provide a model that may explain associations in the patterns of gene expression in breast cancer. Approximately 20% of breast cancers demonstrate intense staining for p53 by immunohistochemistry, which indicates the presence of a missense mutation that stabilizes the p53 protein. Numerous studies of breast cancers have reported an association between expression of p53 by immunohistochemistry (hence, stabilizing p53 mutations) and a lack of expression of estrogen receptor-␣ (ER␣) and overexpression of c-ErbB2 (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) . Interestingly, the expression in breast cancer of both ER␣ and ErbB2 has been shown to be regulated by AP2 factors (3, 12, 14, 22) . Functional promoter studies indicate that AP2␣ can transactivate the ER␣ promoter (22, 24) and may be involved in repression of ErbB2 expression (53, 54) . Studies of the expression of AP2 factors in primary breast cancers have supported the conclusions from promoter analysis. Patterns of expression in breast tumors have demonstrated a statistically significant association between AP2␣ expression and ER␣ expression (55) , and within ER␣-positive tumors, there was a positive correlation between the level of AP2␣ and the expression of ER␣ (15) . There was also an inverse correlation between AP2␣ expression and expression of ErbB2 (15) , supporting the promoter studies that suggested that AP2␣ may inhibit ErbB2 gene expression. The interaction between AP2␣ and p53 could provide a mechanism to explain why breast cancers with nuclear accumulation of p53 are ER␣-negative and ErbB2-positive. For example, it is plausible that the accumulation of mutated p53 protein results in the formation of p53-AP2␣ complexes that are transcriptionally inactive. Such a situation could account for the simultaneous loss of ER␣ and overexpression of ErbB2.
Similarly, the interaction between p53 and AP2␣ may account for patterns of gene expression in colon cancer. Approximately 50 -60% of colon tumors harbor p53 mutations as evidenced by intense staining for p53 by immunohistochemistry and within this group of tumors, ϳ20% will have intense p21 expression (21) . This situation has been explained by a presumed "p53-independent" mechanism of p21 activation. However, our data suggest the possibility that some mutations of p53 may be complemented through an interaction with AP2␣. Therefore, our model predicts that colon cancers with mutated p53 and intense p21 expression have p53 proteins that can be transcriptionally activated through an association with AP2␣.
AP2␣ has been shown to function as a tumor suppressor in breast cancer, colon cancer, and malignant melanoma. We conclude that the mechanism of tumor suppressor activity of AP2␣ is mediated, at least in part, through an augmentation of p53 transcriptional activation. The oncogenes of SV40 (T antigen) (56, 57) , adenovirus (E1B) (58) , and papilloma virus (E6) (59) have been shown to target p53 and the interaction between p53 and these viral oncogenes is required for transformation. Our results now demonstrate that a cellular tumor suppressor gene similarly targets p53. There are likely to be a limited number of pathways through which a tumor suppressor acts to alter cell growth. Our model of the mechanism of AP2␣ tumor suppressor activity lends additional support for a central role for a p53-mediated checkpoint and demonstrates that other tumor suppressor genes can regulate cell growth by modulating p53 activity.
